Anzeige
Mehr »
Login
Freitag, 29.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Spezial am Donnerstag: Rallye II. - Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DTK2 | ISIN: CA4576376012 | Ticker-Symbol: MWG0
Stuttgart
28.03.24
16:05 Uhr
0,311 Euro
-0,002
-0,64 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
INMED PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
INMED PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,3300,35028.03.
0,3070,35728.03.

Aktuelle News zur INMED PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
20.03.InMed Pharmaceuticals Inc. - 8-K, Current Report2
20.03.InMed Pharmaceuticals gets 180-Day extension to regain compliance with Nasdaq4
20.03.InMed Pharmaceuticals: InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance216Vancouver, British Columbia--(Newsfile Corp. - March 20, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the manufacturing, development and commercialization...
► Artikel lesen
23.02.InMed Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying3
13.02.InMed Pharmaceuticals GAAP EPS of -$0.19, revenue of $1.24M beats by $0.12M2
13.02.InMed Pharmaceuticals: InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update635Advancing two new preclinical programs in Alzheimer's and Age-Related Macular DegenerationClosed calendar year 2023 with cash position of US$9.5 million164% revenue growth in the commercial BayMedica...
► Artikel lesen
09.02.InMed Pharmaceuticals Inc. - 8-K, Current Report1
09.02.InMed Pharmaceuticals appoints new CFO Netta Jagpal1
09.02.InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer249Vancouver, British Columbia--(Newsfile Corp. - February 9, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the manufacturing, development and commercialization...
► Artikel lesen
25.01.InMed Pharmaceuticals Has Multiple Milestones Coming Up In 2024, With A Focus On Three Conditions With An Unmet Need5
18.01.InMed Pharmaceuticals: InMed to Discuss Its Pharmaceutical Pipeline and 2024 Strategic Priorities in Fireside Chat with Water Tower Research on January 25, 2024 at 1pm ET415Vancouver, British Columbia--(Newsfile Corp. - January 18, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the manufacturing, development and commercialization...
► Artikel lesen
16.01.InMed Pharmaceuticals Inc. - 8-K, Current Report1
16.01.InMed Pharmaceuticals Provides Business Update and Milestones for 2024357Advancing INM-901 as a multimodal treatment option for Alzheimer's DiseaseAdvancing INM-089 in the treatment of Age-related Macular DegenerationActively seeking partnerships to advance INM-755 in DermatologyBayMedica...
► Artikel lesen
21.12.23InMed Pharmaceuticals Inc. - 10-K/A, Annual Report3
20.12.23InMed Pharmaceuticals Inc. - 8-K, Current Report4
19.12.23InMed Pharmaceuticals: InMed Announces Results of 2023 Annual General Meeting 197Vancouver, British Columbia--(Newsfile Corp. - December 19, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development and manufacturing...
► Artikel lesen
11.12.23InMed's (NASDAQ: INM) Latest Research Demonstrates Potential In Treating Alzheimer's With A Rare Cannabinoid Analog6
29.11.23InMed Pharmaceuticals Inc. - 8-K, Current Report4
29.11.23InMed Pharmaceuticals: InMed Expands its Pharmaceutical Pipeline with INM-089 targeting the treatment of Age-Related Macular Degeneration545INM-089 improves retinal function in in vivo preclinical AMD disease modelEstablishes cannabinol (CBN) analog candidate in a new disease targetVancouver, British Columbia--(Newsfile Corp. - November...
► Artikel lesen
14.11.23InMed Pharmaceuticals GAAP EPS of -$0.76, revenue of $901.8M4
Seite:  Weiter >>
41 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1